Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.

ABSTRACT:

Background

Soft-tissue sarcomas (STSs) are heterogeneous and aggressive tumors, with high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a signature of cytotoxic immune response. We hypothesized that ICR might improve the prognostic assessment of early-stage STS.

Methods

We retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables, including metastasis-free survival (MFS).

Results

Thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients' age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative/qualitative scores of immune respon

SUBMITTER: Bertucci F 

PROVIDER: S-EPMC8753443 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature